Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

The Present and Future of Type 1 Diabetes Prevention: Teplizumab and Immunomodulators

1형당뇨병 예방 약물의 현재와 미래: 테플리주맙과 면역조절약물

  • Heeseok Sohn (College of Pharmacy, Pusan National University) ;
  • Sujong Kim (College of Pharmacy, Pusan National University) ;
  • Jeong-Hyun Yoon (College of Pharmacy, Pusan National University)
  • Received : 2024.10.03
  • Accepted : 2024.11.23
  • Published : 2024.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of insulin-producing beta-cells in the pancreas. Genetic variations within the major histocompatibility complex (MHC) significantly influence the development of T1D, with disease progression often indicated by the presence of autoantibodies. Until recently, insulin therapy was the sole treatment for T1D. However, in 2022, the Food and Drug Administration approved teplizumab, an anti-CD3 monoclonal antibody, as a novel immunomodulatory therapy to delay the onset of T1D. Various immunologic agents, including anti-CD antibodies and anti-cytokine autoantibodies, have been investigated across various stages of T1D in clinical trials. This article examines the current status of drug development for the prevention and treatment of T1D and summarizes key studies that aimed at delaying the onset of T1D using these agents. While efforts to halt or prevent the disease prior to clinical diagnosis have yielded limited success, post-diagnosis interventions have shown promising potential in slowing disease progression by preserving beta-cell function. Further investigation into long-term clinical outcomes related to the delay of T1D onset is necessary, and ongoing studies require extended follow-up to assess their full potential.

Keywords

Acknowledgement

이 논문은 부산대학교 기본연구지원사업(2년)에 의하여 연구되었음.

References

  1. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314(21):1360-8. 
  2. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes develop?: The notion of homicide or β-cell suicide revisited. Diabetes 2011;60(5):1370-9. 
  3. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383(9911):69-82. 
  4. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464(7293):1293-300. 
  5. Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: A modelling study. Lancet Diabetes Endocrinol 2022;10(10):741-60. 
  6. Keam SJ. Teplizumab: First approval. Drugs 2023;83(5):439-45. 
  7. Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019;381(7):603-13. 
  8. Skyler JS. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab Rev 1987;3(4):1017-35. 
  9. Stiller CR, Dupré J, Gent M, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223(4643):1362-7. 
  10. von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 2013;172(2):186-202. 
  11. Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2(1):a007732. 
  12. Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem 2011;57(2):176-85. 
  13. Hull CM, Peakman M, Tree TIM. Regulatory T cell dysfunction in type 1 diabetes: What's broken and how can we fix it? Diabetologia 2017;60(10):1839-50. 
  14. Shapiro MR, Thirawatananond P, Peters L, et al. De-coding genetic risk variants in type 1 diabetes. Immunol Cell Biol 2021;99(5):496-508. 
  15. Eringsmark Regnéll S, Lernmark A. The environment and the origins of islet autoimmunity and type 1 diabetes. Diabet Med 2013;30(2):155-60. 
  16. Knip M, Simell O. Environmental triggers of type 1 diabetes. Cold Spring Harb Perspect Med 2012;2(7):a007690. 
  17. Arif S, Tree TI, Astill TP, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004;113(3):451-63. 
  18. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and longterm type 1 diabetes patients. J Exp Med 2012;209(1):51-60. 
  19. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2(7892):1279-83. 
  20. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010;32(4):468-78. 
  21. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001;358(9277):221-29. 
  22. Redondo MJ, Oram RA, Steck AK. Genetic risk scores for type 1 diabetes prediction and diagnosis. Curr Diab Rep 2017;17(12):129. 
  23. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the endocrine society, and the American diabetes association. Diabetes Care 2015;38(10):1964-74. 
  24. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309(23):2473-9. 
  25. Michels A, Zhang L, Khadra A, Kushner JA, Redondo MJ, Pietropaolo M. Prediction and prevention of type 1 diabetes: Update on success of prediction and struggles at prevention. Pediatr Diabetes 2015;16(7):465-84. 
  26. Knip M, Virtanen SM, Seppä K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010;363(20):1900-8. 
  27. Vaarala O, Ilonen J, Ruohtula T, et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med 2012;166(7):608-14. 
  28. Knip M, Åkerblom HK, Becker D, et al. Hydrolyzed infant formula and early β-cell autoimmunity: A randomized clinical trial. JAMA 2014;311(22):2279-87. 
  29. Knip M, Åkerblom HK, Al Taji E, et al. Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes: The TRIGR randomized clinical trial. JAMA 2018;319(1):38-48. 
  30. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: The babydiet study. Diabetes Care 2011;34(6):1301-5. 
  31. Assfalg R, Knoop J, Hoffman KL, et al. Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia 2021;64(5):1079-92. 
  32. Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: The GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open 2019;9(6):e028578. 
  33. U.S. National library of medicine: Clinicaltrials.Gov. PINIT study: Primary intranasal insulin trial. Available from https://clinicaltrials.Gov/study/nct03182322. Accessed September 19, 2024. 
  34. Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: A randomized clinical trial. JAMA 2017;318(19):1891-902. 
  35. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: A double-blind, randomised controlled trial. Lancet 2008;372(9651):1746-55. 
  36. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346(22):1685-91. 
  37. Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatr Diabetes 2018;19(3):410-9. 
  38. Gale EA, Bingley PJ, Emmett CL, Collier T. European nicotinamide diabetes intervention trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363(9413):925-31. 
  39. U.S. National Library of Medicine: Clinicaltrials.Gov. Prevention trial: Immune-tolerance with alum-gad (Diamyd) and vitamin D3 to children with multiple islet autoantibodies (DiAPREV-IT2). Available from https://clinicaltrials.Gov/study/nct02387164. Accessed September 19, 2024. 
  40. U.S. National Library of Medicine: Clinicaltrials.Gov. Hydroxychloroquine in individuals at-risk for type 1 diabetes mellitus (TN22). Available from https://www.Clinicaltrials.Gov/ct2/show/nct03428945. Accessed September 19, 2024. 
  41. Russell WE, Bundy BN, Anderson MS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: A randomized, double-masked, controlled trial. Diabetes Care 2023;46(5):1005-13. 
  42. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European randomized control trial group. Diabetes 1988;37(11):1574-82. 
  43. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319(10):599-604. 
  44. Chase HP, Butler-Simon N, Garg SK, et al. Cyclosporine a for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics 1990;85(3):241-5. 
  45. Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989;38(6):779-83. 
  46. Skyler JS, Lorenz TJ, Schwartz S, et al. Effects of an anti-CD5 immunoconjugate (CD5-Plus) in recent onset type I diabetes mellitus: A preliminary investigation. The CD5 diabetes project team. J Diabetes Complications 1993;7(4):224-32. 
  47. Chaillous L, Lefèvre H, Thivolet C, et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: A multicentre randomised controlled trial. Diabète insuline orale group. Lancet 2000;356(9229):545-9. 
  48. Ludvigsson J, Faresjö M, Hjorth M, et al. Gad treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359(18):1909-20. 
  49. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001;358(9295):1749-53. 
  50. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-8. 
  51. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54(6):1763-9. 
  52. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378(9790):487-97. 
  53. Hagopian W, Ferry RJ, Jr., Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: Two-year results from the randomized, placebo-controlled protégé trial. Diabetes 2013;62(11):3901-8. 
  54. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62(11):3766-74. 
  55. Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N Engl J Med 2023;389(23):2151-61. 
  56. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial. Diabetologia 2013;56(2):391-400. 
  57. Aronson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014;37(10):2746-54. 
  58. Ambery P, Donner TW, Biswas N, Donaldson J, Parkin J, Dayan CM. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study. Diabet Med 2014;31(4):399-402. 
  59. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after cd3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352(25):2598-608. 
  60. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53(4):614-23. 
  61. Keymeulen B, van Maurik A, Inman D, et al. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia 2021;64(2):313-24. 
  62. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011;378(9789):412-9. 
  63. Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year after cessation of treatment. Diabetes Care 2014;37(4):1069-75. 
  64. Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013;1(4):284-94. 
  65. Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 2015;125(8):3285-96. 
  66. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361(22):2143-52. 
  67. Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function: Two-year results. Diabetes Care 2014;37(2):453-9. 
  68. U.S. National Library of Medicine: Clinicaltrials.Gov. Study of safety and efficacy of cfz533 in type 1 diabetes pediatric and young adult subjects (ccfz533x2207). Available from https://clinicaltrials.Gov/study/nct04129528. Accessed September 19, 2024. 
  69. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381(9881):1905-15. 
  70. Greenbaum CJ, Serti E, Lambert K, et al. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight 2021;6(21):e150074. 
  71. Piemonti L, Keymeulen B, Gillard P, et al. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2022;24(9):1840-9. 
  72. U.S. National Library of Medicine: Clinicaltrials.Gov. Clinical phase II/III trial of ustekinumab to treat type 1 diabetes (UST1D2). Available from https://clinicaltrials.Gov/study/nct03941132. Accessed September 19, 2024. 
  73. Gregory JW, Carter K, Cheung WY, et al. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): Trial protocol. BMJ Open 2021;11(10):e049595. 
  74. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: Pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32(7):1244-9. 
  75. Quattrin T, Haller MJ, Steck AK, et al. Golimumab and beta-cell function in youth with new-onset type 1 diabetes. N Engl J Med 2020;383(21):2007-17. 
  76. Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013;1(4):295-305. 
  77. Rosenzwajg M, Salet R, Lorenzon R, et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: A phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 2020;63(9):1808-21. 
  78. CORDIS. Ultra-low dose of IL-2 for the treatment of recently-diagnosed type 1 diabetes. Available from https://cordis.Europa.Eu/project/id/305380. Accessed September 19, 2024. 
  79. Xu G, Chen J, Jing G, Shalev A. Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes 2012;61(4):848-56. 
  80. Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med 2018;24(8):1108-12. 
  81. Forlenza GP, McVean J, Beck RW, et al. Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial. JAMA 2023;329(12):990-9. 
  82. U.S. National Library of Medicine: Clinicaltrials.Gov. Verapamil SR in adults with type 1 diabetes (Ver-A-T1D). Available from https://clinicaltrials.Gov/study/nct04545151. Accessed September 19, 2024. 
  83. Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021;9(8):502-14. 
  84. Waibel M, Thomas HE, Wentworth JM, et al. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial. Trials 2022;23(1):433. 
  85. Waibel M, Wentworth JM, So M, et al. Baricitinib and β-cell function in patients with new-onset type 1 diabetes. N Engl J Med 2023;389(23):2140-50. 
  86. Martin S, Herder C, Schloot NC, et al. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: The randomized DIATOR trial. PLoS One 2011;6(3):e17554. 
  87. Strom A, Kolb H, Martin S, et al. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One 2012;7(3):e33108. 
  88. Zieliński M, Żalińska M, Iwaszkiewicz-Grześ D, et al. Combined therapy with CD4(+) CD25highCD127(-) T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial. Diabetes Obes Metab 2022;24(8):1534-43. 
  89. Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015;64(2):587-92. 
  90. von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021;9(4):212-24. 
  91. Krogvold L, Mynarek IM, Ponzi E, et al. Pleconaril and ribavirin in new-onset type 1 diabetes: A phase 2 randomized trial. Nat Med 2023;29(11):2902-8. 
  92. Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest 2015;125(1):448-55. 
  93. Haller MJ, Gitelman SE, Gottlieb PA, et al. Antithymocyte globulin plus G-CSF combination therapy leads to sustained immunomodulatory and metabolic effects in a subset of responders with established type 1 diabetes. Diabetes 2016;65(12):3765-75. 
  94. Haller MJ, Schatz DA, Skyler JS, et al. Low-dose anti-thymocyte globulin (ATG) preserves β-cell function and improves HbA(1c) in new-onset type 1 diabetes. Diabetes Care 2018;41(9):1917-25. 
  95. Haller MJ, Long SA, Blanchfield JL, et al. Low-dose anti-thymocyte globulin preserves C-peptide, reduces hba(1c), and increases regulatory to conventional t-cell ratios in new-onset type 1 diabetes: Twoyear clinical trial data. Diabetes 2019;68(6):1267-76. 
  96. U.S. National Library of Medicine: Clinicaltrials.Gov. Rituximab and abatacept for prevention or reversal of type 1 diabetes (TN25). Available from https://clinicaltrials.Gov/study/nct03929601. Accessed September 19, 2024. 
  97. Redondo MJ, Gignoux CR, Dabelea D, et al. Type 1 diabetes in diverse ancestries and the use of genetic risk scores. Lancet Diabetes Endocrinol 2022;10(8):597-608.